July 17, 2025 | Aclymate, Carbon Emissions, Carbon footprint, Hybrid Events, Hybrid meetings, Impetus Digital, Pharma meetings, Sustainability, carbon neutral, green pharma, pharma vvents, reduce carbon, sustainable pharma
Impetus Digital was promoted to the Aclymate Silver Tier for their efforts in crafting carbon-neutral virtual and live meetings for life science companies.

A year after Impetus Digital first calculated and offset all of our home office-related emissions, we’re excited to announce that we have now implemented Phase 2 of our journey toward carbon neutrality. As of January 2024, all of the carbon emissions associated with Impetus Digital staff attending hybrid meetings live (i.e., flights, ground transportation for local meetings, and accommodation) have been–and will continue to be–offset. This means that–while we still encourage clients to go fully virtual to cut down on their meeting-associated emissions almost entirely–those opting for a hybrid event can still feel good knowing that any Impetus support staff attending the meeting in person is not contributing to the carbon footprint of the event.
In fact, we were recently promoted to the Aclymate Silver Tier for our efforts to date. Plus, we continue to be platinum-certified by the Green Business Benchmark (GBB), demonstrating our commitment to sustainable practices!
Phase 3 and beyond will involve calculating and offsetting the emissions associated with the actual meeting venues, any Impetus business trips for reasons other than attending live client meetings and events (e.g., conference attendance), and the small but non-negligible emissions associated with our online portals. Stay tuned for more updates!
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Cassie Solomon, CEO of The New Group Consulting, dives into the future of innovation, digital technologies, and systems thinking in healthcare. Among many other things, we discuss how organizations can prepare…
A customer story
Laura Towart, Founder & CEO of My Personal Therapeutics, discusses her company’s approach to precision medicine, the barriers patients with cancer face when trying to access personalized treatments, and how…
Kim Shah, CEO of KnowYourMeds, explores digital health, AI, telemedicine, health literacy, and how to ensure a safe return to work amidst the ongoing COVID-19 pandemic. We also dive into…
Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine. We also explore the many different hats he wears as CMO, consultant,…
John Leombruno, CEO of OkRx, shares how his company is working to improve PSP strategy and operations in Canada. He also discusses the impact of COVID-19 on PSPs, digital transformation, clinical…
Chad Walsh, CEO of Sciteline, dives into virtual trials, including their benefits, barriers, and impact on patient-centricity. Among other things, we will discuss data privacy concerns, the role of digital…
Owen Muir, MD, CIO at Brooklyn Minds, explores the secondary effects of COVID-19 on mental health conditions, along with techniques such as deep Transcranial Magnetic Stimulation (dTMS), Mentalization-Based Treatment (MBT), and…
COVID-19 has impacted every aspect of our lives, from the way we shop for groceries to the way we conduct work and interact with healthcare providers and our families.
Impetus Digital launches InSite Eventâ„¢ –Â Â the most comprehensive virtual event platform for life science companies, delivered with white glove service


